132482-06-5

Basic information

• Product Name: tert-butyl (2R)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate
• Synonyms: (R)-tert-Butyl 2-(2-hydroxyethyl)pyrrolidine-1-carboxylate;(R)-1-Boc-2-(2-hydroxyethyl)pyrrolidine;tert-butyl (2R)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate
• CAS NO: 132482-06-5
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Mol File: 132482-06-5.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl (2R)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2R)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate(132482-06-5)
• EPA Substance Registry System: tert-butyl (2R)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate(132482-06-5)

Safety Data

• Hazardous Substances Data: 132482-06-5(Hazardous Substances Data)

Usage

General Description

Tert-butyl (2R)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate is a chemical compound with the molecular formula C11H21NO3. It is a derivative of pyrrolidine and contains a tert-butyl group and a carboxylate group. The compound is an ester formed from the reaction of the hydroxyl group of 2-hydroxyethylpyrrolidine and tert-butyl alcohol with the loss of water. Tert-butyl (2R)-2-(2-hydroxyethyl)pyrrolidine-1-carboxylate is commonly used in the synthesis of pharmaceuticals and organic compounds due to its ability to participate in various chemical reactions and its potential biological activity.

Upstream product

• 132482-05-4 methyl (R)-2-[N(1')-(tert-butoxycarbonyl)pyrrolidin-2'-yl]ethanoate 
• 75-21-8 oxirane 
• 86953-79-9 tert-butyl pyrrolidine-1-carboxylate 
• 59378-82-4 N-(tert-butoxycarbonyl)pyrrolidine-2-carboxaldehyde 
• 59378-81-3 1-(tert-butoxycarbonyl)prolin-2R-ol 
• 340129-94-4 (R)-1-[(1,1-dimethylethoxy)carbonyl]-2-ethenylpyrrolidine 
• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 101555-60-6 2-(R)-carboxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 646062-88-6 (E)-(6-tert-butoxycarbonylamino)-2-hexenal 
• 24424-99-5 di-tert-butyl dicarbonate 
• 344-25-2 D-Prolin 
• 152665-79-7 (R)-tert-butyl 2-(2-diazoacetyl)pyrrolidine-1-carboxylate 

Downstream Products

• 201038-72-4 (R)-1-(2-(1-(3-benzyloxy-benzenesuylfonyl)-pyrrolidin-2-yl)-ethyl)-4-methyl piperidine 
• 261901-57-9 SB 269970 A 
• 1433607-76-1 (2R)-N-Boc-2-(((2-((E)-2-amino-7-(4-fluoro-2-(pyridin-3-yl)phenyl)-4-methyl-7,8-dihydro-6H-quinazolin-5-ylidene)amino)oxy)ethyl)pyrrolidine 
• 1433607-60-3 (E)-2-amino-7-(4-fluoro-2-(pyridin-3-yl)phenyl)-4-methyl-7,8-dihydro-6H-quinazolin-5-one O-(R)-(2-(pyrrolidin-2-yl)ethyl)oxime 

Relevant articles and documents

Boron trifluoride etherate-assisted ring opening of ethylene oxide by a chiral organolithium: Enantioselective synthesis of (R)-N-Boc-2-(2-hydroxyethyl) pyrrolidine

A practical synthesis of (R)-N-Boc-2-(2-hydroxyethyl)pyrrolidine in high enantiomeric purity is described. The synthesis involves BF3· Et2O-assisted ring opening of ethylene oxide by a homochiral carbanion (R)-3, which is derived from sparteine-mediated asymmetric deprotonative lithiation of 1-Boc-pyrrolidine.

Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects

Currently used antipsychotics are characterized by multireceptor mode of action. While antagonism of dopamine D2 receptors is responsible for the alleviation of “positive” symptoms of schizophrenia and the effects at other, particularly serotonergic receptors are necessary for their additional therapeutic effects, there is no consensus regarding an “ideal” target engagement. Here, a detailed SAR analysis in a series of 45 novel azinesulfonamides of cyclic amine derivatives, involving the aryl-piperazine/piperidine pharmacophore, central alicyclic amine and azinesulfonamide groups has led to the selection of (S)-4-((2-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)isoquinoline (62). The polypharmacology profile of 62, characterized by partial 5-HT1AR agonism, 5-HT2A/5-HT7/D2/D3R antagonism, and blockade of SERT, reduced the “positive”-like, and “negative”-like symptoms of psychoses. Compound 62 produced no catalepsy, demonstrated a low hyperprolactinemia liability and displayed pro-cognitive effects in the novel object recognition task and attentional set-shifting test. While association of in vitro features with the promising in vivo profile of 62 is still not fully established, its clinical efficacy should be verified in further stages of development.

QUINAZOLINE DERIVATIVES WITH HSP90 INHIBITORY ACTIVITY

Compounds of general formula (I): or a stereoisomer, tautomer, polymorph, hydrate, solvate, or a pharmaceutically acceptable salt thereof, wherein R is as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as proliferative diseases, e.g. cancers, viral and fungal infections, neurodegenerative or inflammatory diseases or conditions. The invention also relates to the preparation of these compounds as well as to pharmaceutical compositions comprising them.